Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)

Phase 2

Completed

Brief Summary: Primary Objective(s):

* To compare the activity (progression-free survival \[PFS\]) of anastrozole in combination with lonafarnib to that of anastrozole in combination with placebo in subjects with hormone-sensitive ADVANCED breast cancer.

Secondary Objective(s):

* To determine the effects of anastrozole in combination with lonafarnib on objective response, duration of response, overall survival, and safety in subjects with advanced breast cancer. To assess the exposure and pharmacokinetics of lonafarnib and anastrozole in the subject population.

Recruitment & Eligibility

Inclusion Criteria

Postmenopausal women who have histologically-confirmed breast cancer with the following characteristics:
- estrogen and/or progesterone receptor positive,
- locally advanced disease
- distant metastatic disease, stage 4
Subjects eligible for single-agent treatment with aromatase inhibitors for current disease.
Subjects taking biophosphonates are allowed if they begin bisphosphonate therapy AT LEAST two weeks prior to randomization.
Measurable disease (masses with clearly defined margins on radiological images and at least one diameter >=20 mm[>=10 mm if spiral CT]) or evaluable disease (masses with margins not clearly defined on radiological images or with no diameter >= 20 mm). Subjects with bone disease only are permitted if disease is evaluable.
ECOG Performance Status of 0 or 1.
Sufficient bone marrow reserve.
Adequate hepatic and renal function: laboratory values within protocol requirements.

Exclusion Criteria

Subjects who have received more than one regimen of cytotoxic chemotherapy for advanced disease.
Subjects with with CLINICALLY APPARENT brain metastases or extensive visceral disease, including extensive hepatic involvement or pulmonary lymphangitic spread of tumor.
Subjects with prior treatments with FTIs.
Subjects with a known or suspected hypersensitivity to any excipients in the lonafarnib formulation (Providone, Poloxamer 188, croscarmellose sodium, silicon dioxide, and magnesium stearate).

Arm && Interventions

Group	Intervention	Description
Placebo plus Anastrozole	Placebo	Participants receive placebo to lonafarnib PO BID beginning on Day 1 Cycle 1 until Progression of Disease, unacceptable toxicity, or other discontinuation criteria are met; and anastrozole, 1mg PO QD for as long as the participant is receiving placebo
Lonafarnib plus Anastrozole	Lonafarnib	Participants receive lonafarnib 200 mg orally (PO) twice per day (BID) beginning on Day 1 Cycle 1 and continuing until Progression of Disease, unacceptable toxicity, or other discontinuation criteria are met; and anastrozole 1 mg, PO, once per day (QD) for as long as the participant is receiving lonafarnib
Lonafarnib plus Anastrozole	anastrozole	Participants receive lonafarnib 200 mg orally (PO) twice per day (BID) beginning on Day 1 Cycle 1 and continuing until Progression of Disease, unacceptable toxicity, or other discontinuation criteria are met; and anastrozole 1 mg, PO, once per day (QD) for as long as the participant is receiving lonafarnib
Placebo plus Anastrozole	anastrozole	Participants receive placebo to lonafarnib PO BID beginning on Day 1 Cycle 1 until Progression of Disease, unacceptable toxicity, or other discontinuation criteria are met; and anastrozole, 1mg PO QD for as long as the participant is receiving placebo

Primary Outcome Measures

Name	Time	Method
Progression-free survival (PFS)	When approximately 70 subjects have progressed

Secondary Outcome Measures

Name	Time	Method
To access the exposure and pk of lonafarnib and anastrazole in the subject population.	When approximately 70 subjects have progressed
Objective response rate (adjusted RECIST criteria), duration of response, and overall survival	When approximately 70 subjects have progressed